WEBULL

Viatris (VTRS) Draws Fresh Attention Following Pain Management Partnership And Undervalued Narrative

Simply Wall St · 1d ago

Why Viatris Stock Is Back on Investors’ Radar

Viatris (VTRS) is drawing attention after its role as a founding partner in the American Academy of Orthopaedic Surgeons’ new Pain Management Resource Center, a project focused on musculoskeletal pain care.

This partnership arrives as Viatris trades at US$17.33, following a 3.8% move on July 16, 2026. This is prompting questions about how its healthcare collaborations and current valuation fit into a broader investment thesis.

See our latest analysis for Viatris.

For context, Viatris has logged a 39.1% year to date share price return and a 94.3% one year total shareholder return. The recent 3.9% daily move fits into a period of building momentum that investors are watching closely alongside developments like the pain management initiative and insider selling activity.

If Viatris’ recent run has you thinking about what else is moving in healthcare, it could be a good time to scan 39 healthcare AI stocks.

After a 94.3% one year total shareholder return and a share price now close to some analyst targets yet still flagged as expensive by at least one intrinsic value model, is most of Viatris’ potential already priced in or not?

Most Popular Narrative: 55.8% Undervalued

The most followed Viatris narrative pegs fair value at $39.24 per share, far above the last close of $17.33, and frames the current price as a reset rather than a peak.

Viatris was created in 2020 through the merger of Mylan and Upjohn, Pfizer’s division of older, off‑patent medicines. Overnight, it became one of the largest global players in generic drugs and biosimilars, operating in more than 165 countries. The early years were tough: many Upjohn products were in natural decline, the generics market is brutally competitive, and the merger came with a heavy debt load. Investors saw a company that needed to shrink rather than grow, and the stock lagged for years.

Read the complete narrative.

According to Adje1959, this $39.24 fair value leans heavily on Viatris as a cash flow story in transition, with future margins and earnings power doing most of the lifting. Want to see how revenue expectations, profitability assumptions and the chosen discount rate all combine to justify such a large gap to $17.33 without relying on high growth projections or a rich future multiple? The full narrative unpacks the moving parts behind that valuation call.

Result: Fair Value of $39.24 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Viatris still carries risks that could undercut this undervalued thesis, including its recent net income loss of $296.5m and its reliance on user assumptions.

Find out about the key risks to this Viatris narrative.

Next Steps

With sentiment around Viatris split between concern over risks and optimism about potential rewards, it makes sense to check the data yourself and move quickly to form a view using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Viatris?

If Viatris has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St Screener to spot other stocks that match your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.